• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test

by Jasmine Pennic 04/08/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test
Source: MyPhenome genetic obesity test

What You Should Know: 

– Phenomix Sciences (Phenomix), a commercial precision obesity medicine biotechnology company, today announced the initiation of its first prospective, placebo-controlled clinical study. 

– The research will evaluate the MyPhenome™ test’s ability to predict individual patient responses to semaglutide, a GLP-1-based therapy that has become a cornerstone in the treatment of obesity.

First Prospective Clinical Study of Semaglutide Using MyPhenome™ Test

This trial builds upon Phenomix’s robust foundation of research, which includes ongoing real-world clinical data collection and over a decade of scientific investigation led by the company’s co-founders, Mayo Clinic researchers Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D., D.Sc.

The ongoing study is actively enrolling patients and will assess the effectiveness of semaglutide in individuals with obesity who receive either a positive or negative MyPhenome test result for the “Hungry Gut” phenotype, characterized by abnormal satiety. Promising results from a previous retrospective study conducted at the Mayo Clinic indicated that patients identified as Hungry Gut positive by the MyPhenome test experienced nearly twice the weight loss on semaglutide compared to those who tested negative for this phenotype.

MyPhenome Genetic Obesity Test

The MyPhenome genetic obesity test offers a simple and non-invasive approach, utilizing a cheek swab to identify the underlying biological factors, or phenotypes, that contribute to an individual’s obesity. Healthcare providers can then leverage this valuable information to develop tailored treatment strategies, encompassing lifestyle and dietary modifications, as well as targeted medication and/or procedural recommendations.

The anticipated outcomes include improved patient response rates to GLP-1 therapies like semaglutide and a reduction in the unnecessary use of these medications.

“This first-in-human clinical study is another important step for Phenomix in advancing precision obesity treatment,” said Mark Bagnall, CEO of Phenomix Sciences. “As GLP-1 medications reshape obesity treatment, this study ensures they are used more effectively by matching patients to the right interventions based on their biology. Our goal is to support the broader adoption of precision obesity medicine across healthcare, pharmaceuticals, and research.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |